Pörssitiedote30.9.2024 klo 12.30Bulletin from the extraordinary general meeting of Calliditas Therapeutics AB (publ)
Pörssitiedote3.9.2024 klo 10.15Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei
Pörssitiedote13.8.2024 klo 5.00Calliditas Therapeutics: Calliditas Interim Report January to June 2024
Lehdistötiedote5.8.2024 klo 5.00Calliditas Therapeutics: Invitation to the presentation of Calliditas's interim report January - June 2024
Lehdistötiedote26.7.2024 klo 15.00Calliditas Therapeutics: Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy
Pörssitiedote26.7.2024 klo 6.00Calliditas Therapeutics: Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis
Lehdistötiedote4.7.2024 klo 6.30Calliditas Therapeutics: Launch of Phase 3 clinical trial with Nefecon in Japan
Lehdistötiedote18.6.2024 klo 10.15Calliditas Therapeutics: Calliditas provides setanaxib patent update
Pörssitiedote17.6.2024 klo 15.30Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)
Pörssitiedote30.5.2024 klo 18.00Calliditas Therapeutics: Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo[®] for the treatment of IgA nephropathy
Lehdistötiedote28.5.2024 klo 12.00Calliditas Therapeutics Presents Data at the 61[st] European Renal Association Congress
Pörssitiedote28.5.2024 klo 6.30Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation